Literature DB >> 22680335

Zurich Fabry study - prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA.

H Sarikaya1, M Yilmaz, N Michael, A R Miserez, B Steinmann, R W Baumgartner.   

Abstract

BACKGROUND AND
PURPOSE: The etiology of stroke in young patients remains undetermined in up to half of the cases. Data on prevalence of Fabry disease (FD) in young people with cryptogenic ischaemic stroke are limited and controversial. We aimed to evaluate the frequency of unrecognized FD in a cohort of stroke patients at a tertiary stroke center.
METHODS: Patients suffering from first cryptogenic ischaemic stroke or transient ischaemic attack (TIA) at the age of 18-55 years were screened for the presence of FD. We measured the serum activity of α-galactosidase (α-GAL) in all patients. In addition, sequencing of α-GAL gene was performed in men with low enzyme activity and in all women.
RESULTS: Between January, 2006, and October, 2009, we recruited 150 patients (102 men, 48 women) with a mean age of 43 ± 9 years at symptom onset (135 ischaemic stroke, 15 TIA). The α-GAL activity was low in nine patients (6%; six men and three women). Genetic sequencing in six men with low enzyme activity and all 48 women detected no α-GAL gene mutation.
CONCLUSION: Our study suggests that the yield of screening for FD in patients with first cryptogenic ischaemic stroke or TIA is very low. Further large-scale studies are needed to investigate the importance of FD amongst patients with recurrent cryptogenic strokes.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22680335     DOI: 10.1111/j.1468-1331.2012.03737.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Risk factors, aetiology and outcome of ischaemic stroke in young adults: the Swiss Young Stroke Study (SYSS).

Authors:  Barbara Goeggel Simonetti; Marie-Luise Mono; Uyen Huynh-Do; Patrik Michel; Celine Odier; Roman Sztajzel; Philippe Lyrer; Stefan T Engelter; Leo Bonati; Henrik Gensicke; Christopher Traenka; Barbara Tettenborn; Bruno Weder; Urs Fischer; Aekaterini Galimanis; Simon Jung; Rudolf Luedi; Gian Marco De Marchis; Anja Weck; Carlo W Cereda; Ralf Baumgartner; Claudio L Bassetti; Heinrich P Mattle; Krassen Nedeltchev; Marcel Arnold
Journal:  J Neurol       Date:  2015-06-12       Impact factor: 4.849

2.  Prevalence of Fabry disease and GLA c.196G>C variant in Japanese stroke patients.

Authors:  Kiyoshiro Nagamatsu; Yoshiki Sekijima; Katsuya Nakamura; Kimitoshi Nakamura; Kiyoko Hattori; Masao Ota; Yusaku Shimizu; Fumio Endo; Shu-Ichi Ikeda
Journal:  J Hum Genet       Date:  2017-03-09       Impact factor: 3.172

3.  Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia.

Authors:  Laura Fancellu; Walter Borsini; Ilaria Romani; Angelo Pirisi; Giovanni Andrea Deiana; Elia Sechi; Pietro Emiliano Doneddu; Anna Laura Rassu; Rita Demurtas; Anna Scarabotto; Pamela Cassini; Eloisa Arbustini; GianPietro Sechi
Journal:  BMC Neurol       Date:  2015-12-12       Impact factor: 2.474

4.  Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly).

Authors:  Kolja Lau; Nurcan Üçeyler; Tereza Cairns; Lora Lorenz; Claudia Sommer; Magnus Schindehütte; Kerstin Amann; Christoph Wanner; Peter Nordbeck
Journal:  Mol Genet Genomic Med       Date:  2022-02-25       Impact factor: 2.473

Review 5.  Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review.

Authors:  Juan Fernando Ortiz; Jashank Parwani; Paul W Millhouse; Ahmed Eissa-Garcés; Gashaw Hassen; Victor D Cuenca; Ivan Mateo Alzamora; Mahika Khurana; Domenica Herrera-Bucheli; Abbas Altamimi; Adam Atoot; Wilson Cueva
Journal:  Cureus       Date:  2021-11-08

6.  Prevalence of CADASIL and Fabry Disease in a Cohort of MRI Defined Younger Onset Lacunar Stroke.

Authors:  Laura L Kilarski; Loes C A Rutten-Jacobs; Steve Bevan; Rob Baker; Ahamad Hassan; Derralynn A Hughes; Hugh S Markus
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.